Literature DB >> 9723784

Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain.

H Hirata1, M Asanuma, J L Cadet.   

Abstract

Methamphetamine (METH) is a drug of abuse that causes deleterious effects to brain monoaminergic systems. These toxic effects are thought to be due to oxidative stress. The pineal hormone, melatonin, has been shown to have neuroprotective effects against toxic quinones and oxidative stress produced by catecholamines. The present study was thus undertaken to assess possible protective effects of melatonin against METH-induced neurotoxic effects on the striatum and the nucleus accumbens by using autoradiographic techniques. Four dosages (5, 20, 40, 80 mg/kg) of melatonin were administered to mice intraperitoneally 30 minutes prior to the injections of METH (4 x 5 mg/kg) given at 2-hour intervals. The lowest doses of melatonin (5 mg/kg) had no significant effects against METH-induced toxicity. However, the higher doses (40 or 80 mg/kg) of melatonin significantly attenuated METH-induced toxic effects on both dopamine and serotonin systems. These data provide further evidence for a possible role of oxidative stress in METH-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723784     DOI: 10.1002/(SICI)1098-2396(199810)30:2<150::AID-SYN4>3.0.CO;2-B

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  10 in total

1.  Modulatory effects of melatonin on cadmium-induced changes in biogenic amines in rat hypothalamus.

Authors:  Alejandro Romero; Ana Caride; Natividad Pereiro; Anunciación Lafuente
Journal:  Neurotox Res       Date:  2011-01-11       Impact factor: 3.911

2.  Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity.

Authors:  X Deng; B Ladenheim; L I Tsao; J L Cadet
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

Review 3.  Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?

Authors:  Naveen Kumar Singhal; Garima Srivastava; Sonal Agrawal; Swatantra Kumar Jain; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2011-12-24       Impact factor: 5.590

4.  Sex-Dependent Alterations in the mRNA Expression of Enzymes Involved in Dopamine Synthesis and Breakdown After Methamphetamine Self-Administration.

Authors:  Aaron E Miller; Atul P Daiwile; Jean Lud Cadet
Journal:  Neurotox Res       Date:  2022-07-14       Impact factor: 3.978

5.  Sex differences in neurobehavioral consequences of methamphetamine exposure in adult mice.

Authors:  Delaney L Davis; Daniel B Metzger; Philip H Vann; Jessica M Wong; Kumudu H Subasinghe; Isabelle K Garlotte; Nicole R Phillips; Ritu A Shetty; Michael J Forster; Nathalie Sumien
Journal:  Psychopharmacology (Berl)       Date:  2022-03-26       Impact factor: 4.415

6.  Sex-Specific Alterations in Dopamine Metabolism in the Brain after Methamphetamine Self-Administration.

Authors:  Atul P Daiwile; Patricia Sullivan; Subramaniam Jayanthi; David S Goldstein; Jean Lud Cadet
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

7.  Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice.

Authors:  Anthony J Hutchinson; Jason Ma; Jiabei Liu; Randall L Hudson; Margarita L Dubocovich
Journal:  Psychopharmacology (Berl)       Date:  2013-08-11       Impact factor: 4.530

Review 8.  Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy.

Authors:  M S Petronek; J M Stolwijk; S D Murray; E J Steinbach; Y Zakharia; G R Buettner; D R Spitz; B G Allen
Journal:  Redox Biol       Date:  2021-01-16       Impact factor: 10.787

9.  Neurotoxins: free radical mechanisms and melatonin protection.

Authors:  Russel J Reiter; Lucien C Manchester; Dun-Xian Tan
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 10.  Melatonin-based therapeutics for neuroprotection in stroke.

Authors:  Kazutaka Shinozuka; Meaghan Staples; Cesar V Borlongan
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.